Jacky Vonderscher, Enyo Pharma CEO
October 19, 2022 06:05 AM EDT
Financing
Startups
R&D

Scoop: Af­ter hep B set­back, an Or­biMed-backed NASH biotech hunts for part­ners as it rais­es Se­ries C

Kyle LaHucik

Senior Reporter

Al­most four and a half years af­ter un­cloak­ing a €40 mil­lion Se­ries B, a small French biotech hopes to se­cure an­oth­er round of fi­nanc­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times